What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.
about
Non-systemic drugs: a critical reviewAddressing the challenges of low clearance in drug researchOpportunities in low-level radiocarbon microtracing: applications and new technologyAbsorption, distribution, metabolism, and excretion of [14C]-dasotraline in humans.The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been grantedMass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans.Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy.Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia.Qualitative and quantitative mass spectrometry imaging of drugs and metabolites.Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.Radionuclide decorporation: matching the biokinetics of actinides by transdermal delivery of pro-chelators.Silicon balance in human volunteers; a pilot study to establish the variance in silicon excretion versus intake.Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on HemodialysisTissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis.Metabolites in safety testing: "MIST" for the clinical pharmacologist.Early human ADME using microdoses and microtracers: bioanalytical considerations.From definition to implementation: a cross-industry perspective of past, current and future MIST strategies.Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?Preclinical in vivo ADME studies in drug development: a critical review.The early estimation of circulating drug metabolites in humans.The generation, detection, and effects of reactive drug metabolites.Metabolite structure analysis by high-resolution MS: supporting drug-development studies.Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.An evaluation of human ADME and mass balance studies using regular or low doses of radiocarbon.Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats.The metabolism and disposition of GSK2140944 in healthy human subjects.Metabolites of alectinib in human: their identification and pharmacological activity.Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans.Pharmacokinetics, absorption, and excretion of radiolabeled revexepride: a Phase I clinical trial using a microtracer and accelerator mass spectrometry-based approach.Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approachesThe fraction dose absorbed, in humans, and high jejunal human permeability relationship.Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteersTrametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.Pharmacokinetics and metabolism of [14C]-tozadenant (SYN-115), a novel A2a receptor antagonist ligand, in healthy volunteers.Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs.Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.
P2860
Q26863371-1FB5A9B6-AD0B-4928-AB7D-ABC29CDE63C8Q26998665-5A01D5DE-7A0C-4745-AAEC-C5E384F3D653Q28817904-9D4F1A2A-4B83-4FDB-8048-4DB9444B87C6Q33771433-4C687D3C-B92C-4B9F-911C-F734A4C31083Q34213739-A85946B6-8888-4BF6-8709-A19B817304A3Q34436863-C3336733-6D83-4FBE-ABFD-B0FE126E83DAQ35586444-2D6B5252-B455-4A22-9919-2618752CD12AQ36364184-9C2F8730-E626-45BF-B4BB-FFC259805D5FQ37080047-E7B811D3-F60B-4562-AA03-2D428CB4AD61Q37150879-1518A72F-5858-47DC-82C1-D520AC131B26Q37207798-6D24750E-EA78-4CA6-AF4E-E5122C3520B2Q37551952-F1A5D810-BA5D-4D8B-812E-7F5F37DD0C15Q37595124-3721814B-C425-4EED-A7CD-E22A1189B67BQ37600402-7713E4A1-6976-48F8-B653-09BE6189F3B0Q37682594-F735D545-E10C-4675-A991-C7E0744C4F64Q37810234-7453006A-7BE3-4E1C-B636-2F46B9F3E625Q37859007-2F971033-6876-4404-959E-2CA40A17739DQ37944852-73643E39-39AB-4FFC-8E6C-7A26223DE061Q37976124-AB8027B9-A984-44B1-B6ED-B910BDC5EB31Q38017286-4022D5FC-574D-43FC-8C78-AB9B65453CCCQ38054629-B71A0903-4A4B-40DD-91BF-1DF8570017CAQ38081958-F841E85E-D660-436B-8D5D-C6CA9E7113BDQ38836158-C66D5840-0A3C-46C2-A2E3-55789EDE74C1Q38855314-2F5B7AC6-85C1-43AF-8893-0408451386F8Q39034625-3C91B47E-B186-4ADE-B9AF-C7BFEB709F39Q39045210-A0A99DC2-6055-4015-8C7C-BEC4BB7BE60FQ40035130-8131EA2A-8289-407B-9401-2F6690B6B1E6Q40903102-90E1068B-0049-4075-952F-A28D00C641F2Q40991511-3A266C48-7C61-4811-87DF-A52F3F5BF84DQ41128320-6BCB5F6C-5753-4578-BF04-06C5F893C0E2Q41265603-513D58AE-72D3-4024-AFBA-38705D3680ADQ41537666-51C28F48-342B-4251-8DD7-C429FD382E40Q41880361-D300CF31-B65A-4B91-92D8-C2214BF8B517Q42131253-DAAEFDF7-B80A-4465-8D04-7E093E6DDDA1Q42576977-A72592E4-7CFA-43BF-B956-2B54D147D75AQ43543302-6B259B61-E9D3-40D0-98DE-777F59AE389AQ46425542-845B65D2-C059-427C-8C06-8673EEF7763BQ46506500-7CBFE871-2C31-4083-AF4F-C0BD94AB56C4Q46542551-052FFEFA-FD5D-45F8-9878-77C916B9081CQ46626956-5B4B212D-C4CB-41A9-AAE4-2C7794D59F46
P2860
What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
What is the objective of the m ...... employing radiolabeled drugs.
@ast
What is the objective of the m ...... employing radiolabeled drugs.
@en
type
label
What is the objective of the m ...... employing radiolabeled drugs.
@ast
What is the objective of the m ...... employing radiolabeled drugs.
@en
prefLabel
What is the objective of the m ...... employing radiolabeled drugs.
@ast
What is the objective of the m ...... employing radiolabeled drugs.
@en
P2093
P2860
P1476
What is the objective of the m ...... employing radiolabeled drugs.
@en
P2093
Dennis A Smith
Jenny I Gedge
R Scott Obach
Sarah J Roffey
P2860
P356
10.1080/03602530600952172
P407
P577
2007-01-01T00:00:00Z